Marcs Sabatine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Abelacimab trial for AF stopped early due to overwhelming reduction in bleeding

Abelacimab trial for AF stopped early due to overwhelming reduction in bleeding
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoErik swainDan bloomfieldLewis dexterMarcs sabatineZora biosciencesByregina schafferJanssen bayerRegeneron pharmaceuticalsSoftcell medicalNovo nordiskJanssen researchBiopharma incBoehringer ingelheimHarvard medical schoolNational blood clot alliance

Atrial Fibrillation Study with Abelacimab Stopped Early by the Data Monitoring Committee Due to an Overwhelming Reduction in Bleeding as Compared to a DOAC

Abelacimab, a Dual-Acting Factor XI / XIa Inhibitor, Demonstrated an Unprecedented Reduction in Bleeding in the Largest and Longest Head-toHead Study Comparing a Factor XI Inhibitor to a DOAC

United statesLewis dexterThromb haemostMarcs sabatineDan bloomfieldColl cardiolHarvard medical schoolData monitoring committeeBlackstone life sciencesStudy groupNational blood clot allianceAnthos therapeutics incAnthos therapeuticsDistinguished chairCardiovascular medicineMyocardial infarction

Abelacimab Demonstrates Overwhelming Efficacy vs Rivaroxaban in Phase 2b Trial

Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.

Marcs sabatineDan bloomfieldLewis dexterStudy groupInternational society on thrombosisData monitoring committeeDistinguished chairCardiovascular medicineMyocardial infarctionAnthos therapeuticsNew england journalInternational societyChief medical officerAbelcimab anthos therapeuticsAtrial fibrillation

Statins Boost Glycemia Slightly, but CVD Benefits Prevail

Meta-analysis of 23 trials confirmed statins raise glycemia and can trigger diabetes, but the effect pales in comparison to their CVD prevention.

United statesNorthwestern universityMarcs sabatineDavid preissBrendanm everettAmerican heart associationOxford england universityHarvard medical schoolGlycemia increasesOutweighs risksUnited kingdom biobankThan counterbalancedIpid managementLipid lowering drugsRug lipid loweringMeta analysis

Type 1 vs Type 2 MI: Search for Differentiating Biomarkers Proves Fruitless

Type 1 vs Type 2 MI: Search for Differentiating Biomarkers Proves Fruitless
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.

United statesCzech republicMarcs sabatineWalter lichtensteinOrion pharmaThomas nestelbergerLiz meszarosBeckman coulterHarvard medical schoolSwiss national science foundationUniversity of baselUniversity hospital baselUniversity baselDeputy editorDeputy managing editorProfessor dr max clo